In this presentation from the “20th Annual Perspectives in Thoracic Oncology”, Dr. Mark A. Socinski discusses whether or not the choice of systemic agents or their sequencing makes a different in combined modality therapy for locally-advanced non-small cell lung cancer (NSCLC).
A continuing education program is offered as a supplement to this webcast at the following location:
http://elc.imedex.com/ELC/Activity-Search.aspx?search=7190
© 2015 Imedex, LLC.